Eplerenone: 6 agencies, 2004–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 20.6 years separate the first record, 13 Dec 2004 at SMC (Scotland), from the most recent, 2025 at PBAC (Australia).
SMC (Scotland) changed its position: restricted on 13 Dec 2004, recommended by 9 Jul 2012.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for eplerenone by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 16 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess eplerenone, on 13 Dec 2004; PBAC (Australia) did not open a file until 2025 — an unusually long tail of 20.6 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 12 years in total.
Restriction is doing real work here: 3 of 11 decisive outcomes narrowed eplerenone to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), PHARMAC (New Zealand) and SMC (Scotland).
4 of the 6 agencies here assessed eplerenone more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for eplerenone.
The full ledger for eplerenone reads 7 recommended, 4 other, 3 restricted and 1 deferred, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Heart failure | Recommended | source |
| HIRA (South Korea) | 9 Jul 2021 | 이텍스 고혈압 , 만성 심부전 | reimbursable only at the evaluated price | source |
| PHARMAC (New Zealand) | 8 May 2019 | Heart failure: ejection fraction <=40%, and diabetes or a risk of diabetes | PTAC advice: Decline · decision reached | source |
| HAS (France) | 28 May 2014 | Re-assessment of SMR and ASMR | ASMR V | source |
| AWMSG (Wales) | 23 Jan 2013 | In addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients … | recommended (full) | source |
11 further decisions for eplerenone, across 4 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- pitolisant — also decided by HIRA in 2021Q3
- albutrepenonacog alfa — also decided by HIRA in 2021Q3
- gilteritinib — also decided by HIRA in 2021Q3
- adalimumab — also decided by PHARMAC in 2021Q2
- rituximab — also decided by PHARMAC in 2021Q2
- carglumic acid — also decided by PHARMAC in 2021Q2
Coverage: 16 decisions for eplerenone from 6 agencies, 2004 to 2025. Data to 7 Sep 2026. ATC class C03D — Diuretics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.